Woodline Partners’s Phathom Pharmaceuticals PHAT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $1.8M | Sell |
187,291
-564,401
| -75% | -$5.41M | 0.01% | 738 |
|
|
2025
Q1 | $4.71M | Sell |
751,692
-250,000
| -25% | -$1.57M | 0.03% | 523 |
|
|
2024
Q4 | $8.13M | Sell |
1,001,692
-1,571,720
| -61% | -$12.8M | 0.06% | 392 |
|
|
2024
Q3 | $46.5M | Buy |
2,573,412
+1,787,422
| +227% | +$32.3M | 0.39% | 68 |
|
|
2024
Q2 | $8.1M | Buy |
785,990
+219,551
| +39% | +$2.26M | 0.08% | 275 |
|
|
2024
Q1 | $6.02M | Sell |
566,439
-529,682
| -48% | -$5.63M | 0.06% | 335 |
|
|
2023
Q4 | $10M | Buy |
1,096,121
+356,100
| +48% | +$3.25M | 0.11% | 226 |
|
|
2023
Q3 | $7.67M | Buy |
740,021
+66,333
| +10% | +$688K | 0.09% | 250 |
|
|
2023
Q2 | $9.65M | Buy |
+673,688
| New | +$9.65M | 0.11% | 211 |
|
|
2021
Q4 | – | Sell |
-29,903
| Closed | -$960K | – | 764 |
|
|
2021
Q3 | $960K | Buy |
+29,903
| New | +$960K | 0.02% | 518 |
|
|
2021
Q2 | – | Sell |
-41,678
| Closed | -$1.57M | – | 622 |
|
|
2021
Q1 | $1.57M | Buy |
+41,678
| New | +$1.57M | 0.03% | 316 |
|